{"product_id":"coronavirus-disease-2019-covid-19-epidemiology-pathogenesis-diagnosis-and-therapeutics-9789811548130","title":"Coronavirus Disease 2019 (COVID-19): Epidemiology, Pathogenesis, Diagnosis, and Therapeutics","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThis book provides a comprehensive overview of recent novel coronavirus (SARS-CoV-2) infection, their biology and associated challenges for their treatment and prevention of novel Coronavirus Disease 2019 (COVID-19). Discussing various aspects of COVID-19 infection, including global epidemiology, genome organization, immunopathogenesis, transmission cycle, diagnosis, treatment, prevention, and control strategies, it highlights host-pathogen interactions, host immune response, and pathogen immune invasion strategies toward developing an immune intervention or preventive vaccine for COVID-19.\u003c\/p\u003e  \u003cp\u003eAn understanding of the topics covered in the book is imperative in the context of designing strategies to protect the human race from further losses and harm due to SARS-CoV-2 infection causing COVID-19.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cb\u003eChapter 1\u003c\/b\u003e_Global trends in epidemiology of Coronavirus Disease 2019 (COVID-19). -Chapter 1.1. Introduction. -Chapter 1.2. 21\u003csup\u003est \u003c\/sup\u003ecentury SARS-CoV-2 outbreaks, epidemics. -Chapter 1.3.Worldwide surveillance systems. -Chapter 1.4. Regions of potential threat. -Chapter 1.5. Pandemic SARS-CoV-2. -Chapter 1.6. Conclusions. -Chapter 1.7. Future Perspectives. -Chapter 1.8. References. -\u003cb\u003eChapter 2\u003c\/b\u003e_Genome organization and Pathogenesis of novel Coronavirus 2019 (SARS-CoV-2)\u003cb\u003e.\u003c\/b\u003e -Chapter 2.1. Introduction\u003cb\u003e.\u003c\/b\u003e -Chapter 2.2. Structure and genome of SARS-CoV-2\u003cb\u003e.\u003c\/b\u003e -Chapter 2.3. Replication and life cycle of virus\u003cb\u003e.\u003c\/b\u003e -Chapter 2.3.1 Attachment\u003cb\u003e.\u003c\/b\u003e -Chapter 2.3.2.Entry\u003cb\u003e.\u003c\/b\u003e -Chapter 2.3.3. Receptors\u003cb\u003e.\u003c\/b\u003e -Chapter 2.3.4. Uncoating\u003cb\u003e.\u003c\/b\u003e -Chapter 2.3.5. Synthesis of viral RNA\u003cb\u003e.\u003c\/b\u003e -Chapter 2.3.6. Viral proteins \u003cb\u003e.\u003c\/b\u003e -Chapter 2.3.7. Egress\u003cb\u003e.\u003c\/b\u003e -Chapter 2.4. Conclusions\u003cb\u003e.\u003c\/b\u003e -Chapter 2.5. Future Perspectives\u003cb\u003e. \u003c\/b\u003e-\u003cb\u003eChapter 3\u003c\/b\u003e_Host immune response against human SARS-CoV-2 infection.\u003cb\u003e \u003c\/b\u003e-Chapter 3.1. Introduction\u003cb\u003e.\u003c\/b\u003e -Chapter 3.2. Immune response\u003cb\u003e.\u003c\/b\u003e -Chapter 3.3. Humoral immune response\u003cb\u003e.\u003c\/b\u003e -Chapter 3.4.Cellular immune response\u003cb\u003e.\u003c\/b\u003e -Chapter 3.5. Conclusions\u003cb\u003e.\u003c\/b\u003e -Chapter 3.6. Future Perspectives\u003cb\u003e.\u003c\/b\u003e -\u003cb\u003eChapter 4\u003c\/b\u003e_Emergence and Re-emergence of SARS Coronaviruses\u003cb\u003e.\u003c\/b\u003e -Chapter 4.1. Introduction\u003cb\u003e.\u003c\/b\u003e -Chapter 4.2. SARS-CoV to SARS-CoV-2: RNA recombination, antigenic shift and antigenic drift\u003cb\u003e.\u003c\/b\u003e -Chapter 4.3. Conclusions\u003cb\u003e.\u003c\/b\u003e -Chapter 4.4. Future Perspectives\u003cb\u003e.\u003c\/b\u003e\u003cb\u003e -Chapter 5_\u003c\/b\u003eTransmission cycle of SARS-CoV and SARS-CoV-2. . -Chapter 5.1. Introduction. -Chapter 5.2. Coronavirus Transmission cycle. -Chapter 5.2.1. Transmission among animals. -Chapter 5.2.2. Transmission in animals to human. -Chapter 5.2.3.Transmission among humans. -Chapter 5.2.4. Other hosts. -Chapter 5.3. Conclusions. -Chapter 5.4. Future Perspectives. -\u003cb\u003eChapter 6_\u003c\/b\u003ePreparing for the perpetual challenges of pandemics of Coronavirus infections with special focus on SARS-CoV-2. -Chapter 6.1. Introduction. -Chapter 6.2. Strategies for pandemic preparedness for Coronavirus. -Chapter 6.2.1. Updated Surveillance system. -Chapter 6.2.2. Strategies for implementation of laboratory diagnostic services during pandemics. -Chapter 6.2.3. Management of bulk vaccines, antiviral drugs. -Chapter 6.3. Promoting facilities for treatment and hospitalisation, healthcare personnel, maintenance of hygiene and disinfection during pandemics. -Chapter 6.3.1.Global management strategies of Coronavirus infection. -Chapter 6.3.2.Economic Consequences of pandemic risk. -Chapter 6.3.3.Conclusions. -Chapter 6.3.4. Future Perspectives. -\u003cb\u003eChapter 7.\u003c\/b\u003e Clinical manifestations and diagnosis of human SARS-CoV-2 infection. . -Chapter 7.1. Introduction. -Chapter 7.2. General Symptoms of SARS-CoV-2 infection. -Chapter 7.3. Clinical Course. -Chapter 7.4. Clinical complications. -Chapter 7.5. Diagnosis of SARS-CoV-2. -Chapter 7.6. Conclusions. -Chapter 7.7. Future Perspectives\u003cb\u003e. -Chapter 8.\u003c\/b\u003e Treatment and Drugs for SARS-CoV-2. . -Chapter 8.1. Introduction. -Chapter 8.2. Antiviral drugs for SARS-CoV-2. -Chapter 8.3. Current available drugs, Pharmacokinetics, Toxicity, Efficacy, Resistance, Drug Interactions, Recommendations for Use. . -Chapter 8.4. Complementary and alternative medicines for SARS-CoV-2. . -Chapter 8.5. Conclusions. -Chapter 8.6. Future Perspectives\u003cb\u003e. -Chapter 9.\u003c\/b\u003e Prevention and control strategies for SARS-CoV-2 infection. . -Chapter 9.1. Introduction. -Chapter 9.2. SARS-CoV-2 vaccine development. -Chapter 9.3. Types of Coronavirus vaccines. -Chapter 9.4. Efficacy and effectiveness of Coronavirus vaccines. -Chapter 9.5. Control strategies of Coronavirus infection. -Chapter 9.6. Conclusions","brand":"Springer Verlag, Singapore","offers":[{"title":"Default Title","offer_id":51743213650263,"sku":"9789811548130","price":125.99,"currency_code":"GBP","in_stock":false}],"url":"https:\/\/bookcurl.com\/products\/coronavirus-disease-2019-covid-19-epidemiology-pathogenesis-diagnosis-and-therapeutics-9789811548130","provider":"Book Curl","version":"1.0","type":"link"}